Agios Pharmaceutical (AGIO) 45.22 $AGIO
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 45.22 (-0.01)
Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer
PR Newswire - Tue Jul 12, 11:00PM CDT
Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization. He will play a key role in Flagship's internal venture creation team during the conception and launch of the next generation of pioneering biotechnology companies as well as serve as an ongoing strategic resource for all companies in the Flagship ecosystem supporting their clinical development strategies. Additionally, he will serve on the board of directors of several portfolio companies; he has served on the board of directors of the Flagship company Rubius Therapeutics since 2015.
EDIT: 25.75 (+0.03), TTOO: 6.98 (+1.32), AGIO: 45.22 (-0.01), MCRB: 10.01 (-0.93)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 37.25 (+0.36), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), BMY: 75.64 (+0.83)
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 45.22 (-0.01)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.39 (-0.16), INSY: 15.95 (+0.30), AGIO: 45.22 (-0.01), GNCA: 3.96 (-0.11)
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 45.22 (-0.01)
Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 45.22 (-0.01)
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 60.15 (-0.45), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02), CELGZ: 1.13 (-0.03)
Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 60.15 (-0.45), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 45.22 (-0.01)
Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 45.22 (-0.01)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 45.14 (+0.39), BIIB: 304.77 (+14.84), CNAT: 2.30 (+0.04), AMGN: 173.90 (+1.87), RPRX: 1.95 (-0.17), JNJ: 125.50 (+0.27), GILD: 80.64 (+1.17), GWPH: 95.55 (+1.23), GERN: 2.70 (+0.02), AVEO: 0.98 (-0.02), ICPT: 172.48 (-0.55), AGIO: 45.22 (-0.01), NVS: 83.02 (-0.24)
What's in Store for Agios (AGIO) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:38PM CDT
Agios Pharmaceuticals (AGIO), which is set to report first-quarter 2016 results on May 5, delivered a negative surprise of 300% last quarter.
IPXL: 31.12 (-0.30), JAZZ: 150.37 (-0.60), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Mon May 02, 7:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:30 a.m. ET to report its first quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 45.22 (-0.01)
Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 46.52 (-0.27), AGIO: 45.22 (-0.01), GNCA: 3.96 (-0.11), SNY: 42.42 (-0.21)
Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 50.50 (+0.03), MACK: 5.83 (+0.03), AGIO: 45.22 (-0.01), LLY: 83.19 (+0.30)
Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 50.50 (+0.03), AGIO: 45.22 (-0.01), PRTA: 55.69 (+0.64)
Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA(R) (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
GlobeNewswire - Wed Mar 30, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy. AG-221 and AG-120 are first-in-class, oral, selective, potent inhibitors of mutant IDH2 and IDH1, respectively, and are being developed in collaboration with Celgene.
AGIO: 45.22 (-0.01)
The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 06, 6:32AM CST
What: Shares of Agios Pharmaceuticals , a clinical-stage drug developer primarily focused on researching cancer and rare-disease treatments, were hammered in January, falling 35% based on data from S&P Capital IQ . The primary culprit behind...
AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 45.22 (-0.01)
Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer
PR Newswire - Tue Jul 12, 11:00PM CDT
Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization. He will play a key role in Flagship's internal venture creation team during the conception and launch of the next generation of pioneering biotechnology companies as well as serve as an ongoing strategic resource for all companies in the Flagship ecosystem supporting their clinical development strategies. Additionally, he will serve on the board of directors of several portfolio companies; he has served on the board of directors of the Flagship company Rubius Therapeutics since 2015.
EDIT: 25.75 (+0.03), TTOO: 6.98 (+1.32), AGIO: 45.22 (-0.01), MCRB: 10.01 (-0.93)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 37.25 (+0.36), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), BMY: 75.64 (+0.83)
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 45.22 (-0.01)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.39 (-0.16), INSY: 15.95 (+0.30), AGIO: 45.22 (-0.01), GNCA: 3.96 (-0.11)
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 45.22 (-0.01)
Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 45.22 (-0.01)
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 60.15 (-0.45), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02), CELGZ: 1.13 (-0.03)
Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 60.15 (-0.45), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 45.22 (-0.01)
Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 45.22 (-0.01)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 45.14 (+0.39), BIIB: 304.77 (+14.84), CNAT: 2.30 (+0.04), AMGN: 173.90 (+1.87), RPRX: 1.95 (-0.17), JNJ: 125.50 (+0.27), GILD: 80.64 (+1.17), GWPH: 95.55 (+1.23), GERN: 2.70 (+0.02), AVEO: 0.98 (-0.02), ICPT: 172.48 (-0.55), AGIO: 45.22 (-0.01), NVS: 83.02 (-0.24)
What's in Store for Agios (AGIO) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:38PM CDT
Agios Pharmaceuticals (AGIO), which is set to report first-quarter 2016 results on May 5, delivered a negative surprise of 300% last quarter.
IPXL: 31.12 (-0.30), JAZZ: 150.37 (-0.60), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Mon May 02, 7:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:30 a.m. ET to report its first quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 45.22 (-0.01)
Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 46.52 (-0.27), AGIO: 45.22 (-0.01), GNCA: 3.96 (-0.11), SNY: 42.42 (-0.21)
Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 50.50 (+0.03), MACK: 5.83 (+0.03), AGIO: 45.22 (-0.01), LLY: 83.19 (+0.30)
Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 50.50 (+0.03), AGIO: 45.22 (-0.01), PRTA: 55.69 (+0.64)
Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA(R) (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
GlobeNewswire - Wed Mar 30, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy. AG-221 and AG-120 are first-in-class, oral, selective, potent inhibitors of mutant IDH2 and IDH1, respectively, and are being developed in collaboration with Celgene.
AGIO: 45.22 (-0.01)
The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 06, 6:32AM CST
What: Shares of Agios Pharmaceuticals , a clinical-stage drug developer primarily focused on researching cancer and rare-disease treatments, were hammered in January, falling 35% based on data from S&P Capital IQ . The primary culprit behind...
AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)
